Strategic partnerships NantWorks operates an ecosystem of biotech and healthcare AI companies including ImmunityBio and NantKwest, presenting opportunities for multi-portfolio collaborations, co-development deals, and integrated solutions across vaccines, cell therapies, and AI-driven healthcare platforms.

Global collaboration The 2026 U.S.-Saudi Biotech Alliance Summit and publicized international partnerships indicate openness to cross-border programs, enabling sales plays around joint ventures, technology licensing, and centralized manufacturing capabilities for vaccine and immunotherapy platforms.

Manufacturing scale A major capital commitment to build a plant capable of producing up to one billion vaccines annually by 2025 signals readiness for large-volume contract manufacturing, enabling strategic engagements with health systems, government programs, and CRO/CMO partnerships.

Vaccine and immunotherapy focus Active development in cancer vaccines and cell-based therapies, along with ongoing COVID-19 vaccine initiatives, creates demand for clinical trial support, regulatory consulting, supply chain optimization, and commercialization services for biotech commercialization partners.

Data and tech enablement Adoption of technology stacks including MATLAB, GitHub, New Relic, and collaboration tools suggests opportunities to offer AI/ML data platforms, software as a service for research workflows, and secure analytics for translational medicine and VUI (vaccine/immunotherapy) program management.